Answers are grounded in this paper and cite their sources.
Multicentre cohort study observes diabetic ketoacidosis risk in hospitalized patients receiving SGLT-2 inhibitors, highlighting inpatient safety surveillance.
Sodium glucose co-transporter-2 inhibitors (SGLT-2i) are increasingly being used among hospitalized patients. Our objective was to assess the risk of diabetic ketoacidosis (DKA) among hospitalized patients receiving an SGLT-2i.
No takes yet. Share an insight, caveat, or question.
Sarma et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: